Probiotic Safety - No Guarantees

JAMA Internal Medicine

Volumn 178, Issue 12, 2018, Pages 1577-1578

  Cohen, Pieter A ^a,b  

^a CAMBRIDGE HEALTH ALLIANCE   (United States)

^b Somerville Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; DIETARY SUPPLEMENT; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT;

HUMANS; PROBIOTICS; RISK ASSESSMENT;

EID: 85055439672     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2018.5403     Document Type: Note

References (10)

1. Parker EA, Roy T, D'Adamo CR, Wieland LS. Probiotics and gastrointestinal conditions: an overview of evidence from the Cochrane Collaboration. Nutrition. 2018; 45: 125-134.e11. doi: 10.1016/j.nut.2017.06.024 28870406
2. Kantor ED, Rehm CD, Du M, White E, Giovannucci EL. Trends in dietary supplement use among US adults from 1999-2012. JAMA. 2016; 316 (14): 1464-1474. doi: 10.1001/jama.2016.14403 27727382
3. Yi SH, Jernigan JA, McDonald LC. Prevalence of probiotic use among inpatients: a descriptive study of 145 U.S. hospitals. Am J Infect Control. 2016; 44 (5): 548-553. doi: 10.1016/j.ajic.2015.12.001 26822808
4. Khalesi S, Bellissimo N, Vandelanotte C, Williams S, Stanley D, Irwin C. A review of probiotic supplementation in healthy adults: helpful or hype? [published online March 26, 2018]. Eur J Clin Nutr. doi: 10.1038/s41430-018-0135-9 29581563
5. Hempel S, Newberry S, Ruelaz A, Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep). 2011; 200 (200): 1-645. 23126627
6. Sanders ME, Akkermans LMA, Haller D, Safety assessment of probiotics for human use. Gut Microbes. 2010; 1 (3): 164-185. doi: 10.4161/gmic.1.3.12127 21327023
7. Bafeta A, Koh M, Riveros C, Ravaud P. Harms reporting in randomized controlled trials of interventions aimed at modifying microbiota: a systematic review. Ann Intern Med. 2018; 169 (4): 240-247. doi: 10.7326/M18-0343 30014150
8. Vallabhaneni S, Walker TA, Lockhart SR,; Centers for Disease Control and Prevention (CDC). Notes from the field: fatal gastrointestinal mucormycosis in a premature infant associated with a contaminated dietary supplement-Connecticut, 2014. MMWR Morb Mortal Wkly Rep. 2015; 64 (6): 155-156. 25695322
9. Egervärn M, Lindmark H, Olsson J, Roos S. Transferability of a tetracycline resistance gene from probiotic Lactobacillus reuteri to bacteria in the gastrointestinal tract of humans. Antonie Van Leeuwenhoek. 2010; 97 (2): 189-200. doi: 10.1007/s10482-009-9401-0 19997864
10. Food and Drug Administration. Draft guidance for industry: policy regarding quantitative labeling of dietary supplements containing live microbials: guidance for industry. https://www.federalregister.gov/documents/2018/09/07/2018-19367/policy-regarding-quantitative-labeling-of-dietary-supplements-containing-live-microbials-draft. Accessed September 7, 2018